[{"id":"cf184e9d-6283-4e58-bcf4-4d7a0f834bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT02592577","created_at":"2021-01-18T12:34:53.573Z","updated_at":"2024-07-02T16:36:32.122Z","phase":"Phase 1","brief_title":"MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC","source_id_and_acronym":"NCT02592577","lead_sponsor":"Adaptimmune","biomarkers":" EGFR • PD-L1 • ALK • ROS1 • HLA-A","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • HLA-A*02","tags":["EGFR • PD-L1 • ALK • ROS1 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADP-A2M10"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 03/11/2020","primary_completion_date":" 03/11/2020","study_txt":" Completion: 03/17/2021","study_completion_date":" 03/17/2021","last_update_posted":"2021-04-09"},{"id":"29d1a6de-03d4-40da-81db-930ad688b10e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02989064","created_at":"2021-06-30T14:53:03.714Z","updated_at":"2024-07-02T16:36:37.092Z","phase":"Phase 1","brief_title":"MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers","source_id_and_acronym":"NCT02989064","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADP-A2M10"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/18/2019","primary_completion_date":" 12/18/2019","study_txt":" Completion: 06/04/2020","study_completion_date":" 06/04/2020","last_update_posted":"2020-12-19"}]